Merck & Co (MRK)

MERCK & CO. INC. (NYSE:MRK) is a value stock with strong profitability, a healthy balance sheet, and an attractive dividend. Trading below industry valuations, it may appeal to long-term investors.

Merck's oral PCSK9 inhibitor enlicitide showed significant LDL-C reductions in two Phase 3 trials, with no major safety concerns reported.

Dean Y. Li, president of Merck Research Laboratories, said that the company is working with urgency to make the oral therapy available to patients worldwide.

As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the S&P500 stocks leading the pack in terms of gains and losses.

Each of the index's highest-yielding names has its own unique story right now.

Byron Allen dials out, Salesforce logs in. Here are the various deal announcements of the past week plus bankruptcy updates.

Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives.

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.

The deal is being discussed ahead of key data from MoonLake in patients with a skin disease.

Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it faces revenue pressure from Keytruda's looming patent cliff.

Merck shared safety and efficacy results of MK-1084; either as monotherapy or in combinations, it demonstrated a manageable safety profile.

There's a long history of anti-PD-1 and anti-VEGF drugs working to slow progression, but not improve overall survival.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

The decision is based on results from a late-stage trial in which the drug failed to prolong patients' lives, the companies stated.

Keros ends PAH development of cibotercept after Phase 2 safety issues, including pericardial effusions, and plans to cut 45% of workforce amid review.